Fintel reports that on January 9, 2026, BTIG upgraded their outlook for MoonLake Immunotherapeutics (NasdaqCM:MLTX) from Neutral to Buy.
Analyst Price Forecast Suggests 34.04% Upside
As of December 21, 2025, the average one-year price target for MoonLake Immunotherapeutics is $19.22/share. The forecasts range from a low of $2.02 to a high of $89.25. The average price target represents an increase of 34.04% from its latest reported closing price of $14.34 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for MoonLake Immunotherapeutics is 0MM. The projected annual non-GAAP EPS is -1.47.
What is the Fund Sentiment?
There are 265 funds or institutions reporting positions in MoonLake Immunotherapeutics. This is an increase of 4 owner(s) or 1.53% in the last quarter. Average portfolio weight of all funds dedicated to MLTX is 0.17%, an increase of 66.85%. Total shares owned by institutions decreased in the last three months by 33.86% to 41,493K shares. 
The put/call ratio of MLTX is 0.19, indicating a bullish outlook.
What are Other Shareholders Doing?
Bvf holds 19,751K shares representing 27.67% ownership of the company. No change in the last quarter.
Avoro Capital Advisors holds 2,000K shares representing 2.80% ownership of the company. In its prior filing, the firm reported owning 4,150K shares , representing a decrease of 107.50%. The firm decreased its portfolio allocation in MLTX by 94.60% over the last quarter.
Cormorant Asset Management holds 1,994K shares representing 2.79% ownership of the company. In its prior filing, the firm reported owning 8,494K shares , representing a decrease of 325.95%. The firm decreased its portfolio allocation in MLTX by 96.70% over the last quarter.
Balyasny Asset Management holds 1,699K shares representing 2.38% ownership of the company. In its prior filing, the firm reported owning 423K shares , representing an increase of 75.10%. The firm decreased its portfolio allocation in MLTX by 48.66% over the last quarter.
Adage Capital Partners Gp, L.l.c. holds 1,500K shares representing 2.10% ownership of the company. In its prior filing, the firm reported owning 0K shares , representing an increase of 100.00%.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
